ArticleTranslational cancer research2026
Prognostic stratification in non-small cell lung cancer using a TIDE-informed transcriptomic signature: model development and validation.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-small cell lung cancer (NSCLC) remains a major cause of cancer mortality. The Tumor Immune Dysfunction and Exclusion (TIDE) score is widely used to estimate immune-checkpoint blockade response, but its broader prognostic relevance in unselected NSCLC populations is unclear. This study aimed to determine whether TIDE-informed strata carry prognostic information beyond immunotherapy settings, and to develop and externally validate an immune gene expression-based prognostic signature derived from differentially expressed genes (DEGs) between these strata. Methods: Gene expression data and clinical information for NSCLC patients (n=1,153) were obtained from The Cancer Genome Atlas (TCGA). TIDE scores were calculated to stratify patients, and least absolute shrinkage and selection operator (LASSO) and Cox regressions were used to identify prognosis-related immune DEGs. A prognostic model was developed and validated using an external dataset (GSE50081, n=127). Immune cell infiltration was assessed using CIBERSORT, while drug sensitivity predictions were made based on the Genomics of Drug Sensitivity in Cancer (GDSC) database. Pathway enrichment analyses, including gene set variation analysis (GSVA) and gene set enrichment analysis (GSEA), were conducted to explore key molecular mechanisms. Results: The prognostic model, based on 24 immune-related DEGs, effectively stratified NSCLC patients into high- and low-risk groups, with significant differences in survival outcomes (P<0.001). Key signaling pathways, including interleukin (IL)-17, p53, and tumor necrosis factor (TNF), were found to be associated with immune-related genes such as Conclusions: The TIDE algorithm carries prognostic information in NSCLC beyond immunotherapy settings. The proposed TIDE-informed gene signature reproduced prognostic stratification across cohorts, suggesting potential applicability to a broader NSCLC population and supporting future personalized risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.